Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
One approach to improving efficacy in MS therapy is to identify medications that provide additive or synergistic benefit in combination. Orally administered cholesterol-lowering HMG-CoA reductase inhibitors (known as statins), which exhibit immunomodulatory properties and are effective in treatment of the MS model EAE, are being tested in MS. As atorvastatin can enhance protective Th2 responses and has a different mechanism of action than glatiramer acetate (GA), a parenterally administered immunomodulatory agent approved for MS treatment, we tested whether the combination of these agents could be beneficial in EAE. Combination therapy using suboptimal doses of atorvastatin and GA prevented or reversed clinical and histologic EAE. Secretion of proinflammatory Th1 cytokines was reduced--and conversely Th2 cytokine secretion was increased--in these mice, but not in mice treated with each drug alone at the same doses. Monocytes treated with the combination of suboptimal doses of atorvastatin and GA secreted an antiinflammatory type II cytokine pattern and, when used as APCs, promoted Th2 differentiation of naive myelin-specific T cells. Our results demonstrate that agents with different mechanisms of immune modulation can combine in a synergistic manner for the treatment of CNS autoimmunity and provide rationale for testing the combination of atorvastatin and GA in MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
Statins as a newly recognized type of immunomodulator.
Kwak, B., Mulhaupt, F., Myit, S., & Mach, F. (2000) · Nature Medicine · doi:10.1038/82219 · Cited by 1,383
Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis
Steinman, L., & Zamvil, S. S. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.08.014 · Cited by 265
Self-citation
Cited by
Statin therapy and autoimmune disease: from protein prenylation to immunomodulation
Greenwood, J., Steinman, L., & Zamvil, S. S. (2006) · Nature Reviews Immunology · doi:10.1038/nri1839 · Cited by 683
Bai, L., Lennon, D. P., Eaton, V., Maier, K., Caplan, A. I., Miller, S. D., & Miller, R. H. (2009) · Glia · doi:10.1002/glia.20841 · Cited by 546
Steinman, L., & Zamvil, S. S. (2006) · Annals of Neurology · doi:10.1002/ana.20913 · Cited by 479
Type II monocytes modulate T cell–mediated central nervous system autoimmune disease
Weber, M. S., Prod'homme, T., Youssef, S., Dunn, S. E., Rundle, C. D., Lee, L., Patarroyo, J. C., Stüve, O., Sobel, R. A., Steinman, L., et al. (2007) · Nature Medicine · doi:10.1038/nm1620 · Cited by 447
“Recent reports indicate that GA treatment may also exert immunomodulatory activity on antigen-presenting cells (APCs”
BackgroundSelf-citationDimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2
Schulze-Topphoff, U., Varrin-Doyer, M., Pekarek, K., Spencer, C. M., Shetty, A., Sagan, S. A., Cree, B. A. C., Sobel, R. A., Wipke, B. T., Steinman, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603907113 · Cited by 293
Statins: Mechanisms of neuroprotection
van der Most, P. J., Dolga, A. M., Nijholt, I. M., Luiten, P. G. M., & Eisel, U. L. M. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.02.002 · Cited by 268
“Animal experiments suggest that a lower dosage of statins combined with glatiramer acetate, 5- aminoimidazole-4-carboxamide-1-b-D-ribofuranoside or rolipram suppresses MS pathology equally or more effectively as a high dose of statins alone (Paintlia et al., 2006, 2009; Stuve et al., 2006).”
Glatiramer acetate: Mechanisms of action in multiple sclerosis
Schrempf, W., & Ziemssen, T. (2007) · Autoimmunity Reviews · doi:10.1016/j.autrev.2007.02.003 · Cited by 168
Cholesterol: A Novel Regulatory Role in Myelin Formation
Saher, G., Quintes, S., & Nave, K.-A. (2011) · The Neuroscientist · doi:10.1177/1073858410373835 · Cited by 144
Glatiramer acetate: mechanisms of action in multiple sclerosis.
Ziemssen, T., & Schrempf, W. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(07)79024-4 · Cited by 135
Costello, F., Stüve, O., Weber, M. S., Zamvil, S. S., & Frohman, E. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328122de1b · Cited by 46
Self-citation
Metadata
- Authors
- Stuve, O.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-03-23
- Volume
- 116
- Issue
- 4
- Pages
- 1037-1044
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2147292685
- Cited by
- 107
- References
- 3
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.